Clinical trial
A Study of Letrozole in the Treatment of Endometrial Cancer
NCT00333086 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00333086 |
|---|---|
| Title | A Study of Letrozole in the Treatment of Endometrial Cancer |
| Official title | A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Canadian Cancer Trials Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent and Metastatic Endometrial Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 36 |
| Start date | Jan 1, 2000 |
| Primary completion | Jun 1, 2006 |
| First posted | Jun 2, 2006 |
| Last update posted | Apr 19, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: